Core Viewpoint - China SXT Pharmaceutics, Inc. will begin trading its Class A Ordinary Shares on The Nasdaq Stock Market under the symbol "SXTC" starting March 24, 2026, following a recent change in its share structure [1]. Group 1: Share Structure Changes - On July 28, 2025, shareholders approved a dual class share structure, creating unlimited Class B Ordinary Shares with 50 votes per share and designating existing shares as Class A Ordinary Shares with no par value [2]. - The Share Re-classification became effective upon the filing of the Amended and Restated Memorandum and Articles of Association with the Companies Registry of the British Virgin Islands [2]. - Shareholders holding shares through banks or brokers will have their shares automatically adjusted to reflect the new share classification [3]. Group 2: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [4]. - The company specializes in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [4].

Company Overview - China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [7] - The company was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [7] Offering Details - Univest Securities, LLC announced the closing of a registered direct offering of approximately $10 million for China SXT Pharmaceuticals [1] - The offering involved the sale of 66,666,666 Class A ordinary shares at a purchase price of $0.15 per share [2] - The gross proceeds from the offering were approximately $10 million, with Univest acting as the sole placement agent [3] Regulatory Compliance - The registered direct offering was made under a shelf registration statement on Form F-3, which became effective on December 1, 2025 [4]

Core Insights - China SXT Pharmaceuticals, Inc. has launched a Strategic Artificial Intelligence (AI) Insights Initiative aimed at integrating AI-driven analytics into its product portfolio planning and market intelligence processes to evolve into a modern TCM enterprise [1][6] Group 1: Initiative Objectives - The primary objective of the initiative is to strengthen the scientific basis of R&D decision-making by analyzing multi-dimensional datasets such as historical sales, regional health demand, product performance trends, and supply dynamics of TCM raw materials [2] - The initiative aims to ensure that the innovation roadmap aligns with evolving consumer needs and competitive shifts in the TCM sector [2] Group 2: Expected Outcomes - Through AI-enabled analytics, the company expects to identify new product opportunities, enhance commercial potential assessment, and strengthen life cycle management for its existing TCMP and TCMHS product lines [3] - Insights gained from this initiative are anticipated to enhance the company's adaptability to macroeconomic changes, regulatory developments, and competitive dynamics, supporting timely adjustments in marketing, pricing, and distribution strategies [3] Group 3: Implementation Strategy - A key component of the initiative includes the development of offline AI-supported TCM consultation stores ("AI Clinics") across China, which will serve as consumer-facing extensions of the company's AI analytics engine [4] - These AI Clinics will utilize proprietary AI algorithms to offer personalized health screenings, targeted recommendations for TCMP and TCMHS products, and tailored diet and lifestyle guidance [5] Group 4: Innovation System - The consumer-facing model is designed to collect reliable real-time information on product efficacy, customer preferences, and user behavior, which will feed back into the company's R&D and product optimization processes, forming an efficient closed-loop innovation system [5] - The integration of AI-driven insights across product planning, market intelligence, and consultation services is seen as a foundation for a more data-informed, consumer-centered, and innovation-driven TCM ecosystem [6]

Core Viewpoint - China SXT Pharmaceuticals, Inc. has regained compliance with Nasdaq's Minimum Bid Price Requirement after a share consolidation and has closed the matter with Nasdaq [1][4]. Group 1: Compliance Notification - The company received a Compliance Notice from Nasdaq on March 13, 2025, confirming it has met the Minimum Bid Price Requirement [1]. - Previously, on October 3, 2024, the company was notified of its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days [2]. - The company was given until April 1, 2025, to regain compliance under Nasdaq Listing Rules [2]. Group 2: Share Consolidation - To address the Minimum Bid Price deficiency, the company executed a share consolidation on February 25, 2025, consolidating every eight ordinary shares into one [3]. - Following the consolidation, the company achieved a closing bid price of at least US$1.00 per share for 10 consecutive business days from February 25, 2025, to March 12, 2025 [4]. Group 3: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [5]. - The company specializes in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [5].